TOP TIERMARKET NEWSWIRE

News & sentiment

RENOVORX INC (RNXT) — News & AI sentiment

RENOVORX INC (RNXT) news roundup. 13 stories aggregated over the last 30 days. Average 30-day sentiment is 58.8/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

0

30d stories

13

avg sentiment 58.8/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

RNXT news in the last 24 hours, 7 days, 30 days and 90 days

How much RNXT coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	RNXT stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	0	—	no coverage
Last 30 days	13	58.8/100	RNXT headlines →
Last 90 days	31	59.4/100	RNXT headlines →

Latest stories on RNXT

These low-priced stocks are flashing overbought signals

Seeking Alpha50 · neutralgeneral

Sep 4

RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline

InvestorsHub67 · bullishproduct/pr

Sep 2

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

StockTitan55 · neutralgeneral

Sep 2

RenovoRx price target raised to $14.50 from $14 at Ascendiant

The Fly61 · neutralanalyst

Aug 28

RenovoRx publishes pharmacokinetic, pharmacodynamic data from TIGeR-PaC trial

The Fly59 · neutralproduct/pr

Aug 25

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

StockTitan63 · neutralproduct/pr

Aug 25

RenovoRx regains Nasdaq compliance

Seeking Alpha58 · neutralgeneral

Aug 21

RenovoRx regains compliance with Nasdaq

The Fly59 · neutralgeneral

Aug 21

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Business Insider58 · neutralgeneral

Aug 21

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire59 · neutralgeneral

Aug 21

RenovoRx, Inc. (RNXT) files 8-K

SEC 8-K50 · neutralgeneral

Aug 20

RenovoRx receives notice of allowance for new RenovoCath U.S. patent

The Fly63 · neutralproduct/pr

Aug 20

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

StockTitan63 · neutralproduct/pr

Aug 20

8-K/A - RenovoRx, Inc. (RNXT) files 8-K

SEC 8-K50 · neutralgeneral

Aug 13

RenovoRx Raises 2026 Guidance as Commercial Adoption Accelerates, Revenue Jumps 61% Sequentially

MarketChameleon73 · bullishearnings

Aug 13

RenovoRx Q2 Earnings Call Highlights

Yahoo Finance67 · bullishearnings

Aug 13

RenovoRx (RNXT) Q2 2026 Earnings Call Transcript

Yahoo Finance67 · bullishearnings

Aug 13

RenovoRx (RNXT) Q2 2026 Earnings Call Transcript

The Motley Fool67 · bullishearnings

Aug 13

RenovoRx GAAP EPS of -$0.06 beats by $0.01

Seeking Alpha56 · neutralearnings

Aug 12

RenovoRx, Inc. (RNXT) files 8-K

SEC 8-K50 · neutralgeneral

Aug 12

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

GlobeNewswire73 · bullishearnings

Aug 12

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

StockTitan73 · bullishearnings

Aug 12

RenovoRx completes enrollment in TIGeR-PaC trial

The Fly59 · neutralproduct/pr

Aug 11

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

StockTitan67 · bullishproduct/pr

Aug 11

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

StockTitan63 · neutralproduct/pr

Aug 6

Open RNXT in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →